211 related articles for article (PubMed ID: 7519586)
1. Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers.
Flavell DJ; Boehm DA; Okayama K; Kohler JA; Flavell SU
Int J Cancer; 1994 Aug; 58(3):407-14. PubMed ID: 7519586
[TBL] [Abstract][Full Text] [Related]
2. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of HB2 (anti-CD7)--saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice.
Morland BJ; Barley J; Boehm D; Flavell SU; Ghaleb N; Kohler JA; Okayama K; Wilkins B; Flavell DJ
Br J Cancer; 1994 Feb; 69(2):279-85. PubMed ID: 7507691
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
Flavell DJ; Cooper S; Okayama K; Emery L; Flavell SU
Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
Flavell DJ; Flavell SU; Boehm DA; Emery L; Noss A; Ling NR; Richardson PR; Hardie D; Wright DH
Br J Cancer; 1995 Dec; 72(6):1373-9. PubMed ID: 8519647
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
Flavell DJ; Warnes SL; Noss AL; Flavell SU
Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.
Flavell DJ; Boehm DA; Noss A; Flavell SU
Br J Cancer; 1997; 75(7):1035-43. PubMed ID: 9083340
[TBL] [Abstract][Full Text] [Related]
8. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.
Flavell DJ; Warnes S; Noss A; Flavell SU
Cancer Res; 1998 Dec; 58(24):5787-94. PubMed ID: 9865737
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line.
Flavell DJ; Cooper S; Morland B; Flavell SU
Br J Cancer; 1991 Aug; 64(2):274-80. PubMed ID: 1716453
[TBL] [Abstract][Full Text] [Related]
10. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU
Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules.
Flavell DJ; Cooper S; Morland B; French R; Flavell SU
Br J Cancer; 1992 Apr; 65(4):545-51. PubMed ID: 1373293
[TBL] [Abstract][Full Text] [Related]
12. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
14. Immunotoxins containing saporin linked to different CD2 monoclonal antibodies: in vitro evaluation.
Tazzari PL; Bolognesi A; De Totero D; Lemoli RM; Fortuna A; Conte R; Crumpton MJ; Stirpe F
Br J Haematol; 1994 Jan; 86(1):97-105. PubMed ID: 7912101
[TBL] [Abstract][Full Text] [Related]
15. Immunotoxin studies in a model of human T-cell acute lymphoblastic leukemia developed in severe combined immune-deficient mice.
Morland BJ; Boehm D; Flavell SU; Kohler JA; Flavell DJ
Cell Biophys; 1994; 24-25():315-29. PubMed ID: 7736537
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
[TBL] [Abstract][Full Text] [Related]
17. Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies.
Vallera DA; Burns LJ; Frankel AE; Sicheneder AR; Gunther R; Gajl-Peczalska K; Pennell CA; Kersey JH
J Immunol Methods; 1996 Oct; 197(1-2):69-83. PubMed ID: 8890895
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and characterization of an antihuman T-lymphocyte saporin immunotoxin (OKT1-SAP) with in vivo stability into nonhuman primates.
Siena S; Lappi DA; Bregni M; Formosa A; Villa S; Soria M; Bonadonna G; Gianni AM
Blood; 1988 Aug; 72(2):756-65. PubMed ID: 3042047
[TBL] [Abstract][Full Text] [Related]
19. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
Uckun FM; Myers DE; Irvin JD; Kuebelbeck VM; Finnegan D; Chelstrom LM; Houston LL
Leuk Lymphoma; 1993 Apr; 9(6):459-76. PubMed ID: 7687916
[TBL] [Abstract][Full Text] [Related]
20. Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation.
Tazzari PL; Zhang S; Chen Q; Sforzini S; Bolognesi A; Stirpe F; Xie H; Moretta A; Ferrini S
Br J Cancer; 1993 Jun; 67(6):1248-53. PubMed ID: 8512810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
